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Abstract
MYC deregulation is common in human cancer and has a role in
sustaining the aggressive cancer stem cell populations. MYC medi-
ates a broad transcriptional response controlling normal biological
programmes, but its activity is not clearly understood. We address
MYC function in cancer stem cells through the inducible expression
of Omomyc—a MYC-derived polypeptide interfering with MYC
activity—taking as model the most lethal brain tumour, glioblas-
toma. Omomyc bridles the key cancer stemlike cell features and
affects the tumour microenvironment, inhibiting angiogenesis. This
occurs because Omomyc interferes with proper MYC localization
and itself associates with the genome, with a preference for sites
occupied by MYC. This is accompanied by selective repression of
master transcription factors for glioblastoma stemlike cell identity
such as OLIG2, POU3F2, SOX2, upregulation of effectors of tumour
suppression and differentiation such as ID4, MIAT, PTEN, and
modulation of the expression of microRNAs that target molecules
implicated in glioblastoma growth and invasion such as EGFR and
ZEB1. Data support a novel view of MYC as a network stabilizer
that strengthens the regulatory nodes of gene expression networks
controlling cell phenotype and highlight Omomyc as model mole-
cule for targeting cancer stem cells.
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Introduction
MYC is a transcription factor (TF) that regulates a large number of
protein-coding and non-coding genes and coordinates many biologi-
cal processes. Its transcriptional signature is not constant among the
different cell types. MYC is commonly deregulated in human cancer
and is an organizer of cancer stem cells [1,2]. It represents a
primary target for cancer treatment because its inhibition leads to
cancer regression [1]. MYC binds to E-boxes—CACGTG consensus
sequences—at thousands of genomic loci in complex with MAX and
interacts with a number of proteins involved in the regulation of
transcription and chromatin remodelling [3]. MYC does not appear
to induce new transcripts but supports transcript production from
already active genes and promotes transcript elongation [4,5]. The
upregulated targets include microRNAs (miRs) like those in the
miR-17-92 cluster that suppress specific genes to sustain a neoplastic
state [6–9]. MYC also downregulates an important set of genes.
Repression may be either direct, through the association with TFs
such as MIZ1 and EZH2 (catalytic component of the Polycomb
repressive complex) or indirect, by increasing expression of
repressors like SIN3B and EZH2 itself [3,5]. Obtaining a satisfying
explanation of its molecular function has been made hard by the
complexity of its action. Current views consider MYC as either a
universal nonlinear amplifier or a gene-specific modulator
[3,5,10–13].
As MYC supports the processes required for normal growth and
homoeostasis, its ablation is less attractive than modulation of its
expression or function. This view is supported by studies showing
the potential therapeutic efficacy of drugs impairing MYC transcrip-
tion [14–16] and of Omomyc, a ninety amino acid long polypeptide
obtained by targeted mutations of c-MYC bHLHZip domain [17].
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Omomyc affects MYC at the level of protein interactions and DNA
binding and is effective in transgenic tumour models including
glioma, while being well tolerated [18–23]. Further insights into its
mechanism of action may contribute to elucidate the function of
MYC and better indicate how to target it.
Glioblastoma multiforme is the most common and aggressive
brain tumour [24]. It harbours a population of glioblastoma stemlike
cells (GSCs), which are multipotent, resistant to therapies and able
to regenerate the tumour [25,26]. Since MYC is highly expressed in
these cells and is required for maintaining their phenotype [27],
they are a good model for addressing MYC function in cancer stem
cells and the impact of its inhibition by Omomyc.
Results
We employed inducible Omomyc in order to perturb MYC function.
We stably transduced three patient-derived GSCs (BT168, BT275
and BT308) [28] with the SLIK-FO lentivirus driving doxycycline
(Dox)-dependent expression of a FlagOmomyc (FO) construct.
Omomyc was first detectable at 4–8 h post-Dox treatment, reaching
maximal levels at 48 h (Fig 1A).
Influence of MYC inhibition on glioblastoma stemlike
cell behaviour
In vitro
Dox treatment reduced proliferation of GSCFO cells but not of cells
expressing a Dox-inducible green fluorescent protein (Figs 1B and
EV1A). Likewise, it caused a strong decrease of GSC self-renewal
(from > 40 to ~7%) and neurosphere size (Figs 1C and D, and
EV1B). This was mirrored (Figs 1E and EV1D) by the decreased
expression of genes involved in neural stem cell self-renewal and
proliferation: SOX2, NOTCH1, CCND1 (cyclin D1) and NESTIN
[29–32]. On the contrary, expression of PTEN—a tumour suppressor
that inhibits cell renewal, enhances differentiation and is frequently
lost in glioblastoma [33]—increased. The migratory ability of GSCs,
which accounts for their propensity to infiltrate the tumour and
recur at distant sites [34], was strongly restrained (Figs 1F and
EV1C).
We investigated whether Omomyc influenced GSC capacity to
differentiate towards neural cell types when grown as monolayers
in the presence of serum [28]. Upon Dox treatment in the presence
of serum, SOX2 and NESTIN expression was switched off and the
neuronal marker bIII-tubulin was induced faster and remained
higher than control in BT168FO (Fig 1G), BT275FO and BT308FO
(Fig EV1E). The astroglial marker GFAP was inhibited in BT168
cells only, suggesting that Omomyc may specifically enhance
neuronal differentiation in these cells. In conclusion, Omomyc
promoted differentiation in the presence of an appropriate stimulus.
In vivo
To investigate the consequences of MYC inhibition on GSC tumour-
forming ability, we stereotaxically implanted BT168 and BT308 cells
harbouring or not the inducible FlagOmomyc (FO) into the nucleus
caudatum of immune-deficient mice. We induced Omomyc expres-
sion by Dox right after the xenograft and performed tumour engraft-
ment and survival studies. Mice implanted with Omomyc-producing
GSCs survived longer than controls (Fig EV2A and B)—as recently
reported [23]—although the survival difference was moderate, as
they finally showed neurological symptoms due to the presence of
intracranial gliomas and were sacrificed. This is consistent with the
observation that only a fraction of the engrafted cells were able to
keep producing FlagOmomyc in vivo (Fig 2A), likely due to epi-
genetic silencing of the CMV promoter driving its expression. To
better investigate the impact on tumour formation and expression
of key glioblastoma features, we compared brain serial sections of
control and Omomyc-expressing xenografts of mice sacrificed before
the onset of neurological symptoms. The fraction of proliferating
cells in the Omomyc-expressing xenografts was similar to controls
(Ki67 staining in Figs 2B and EV2C) while the density of human cells
was strongly reduced (Fig 2H), indicating that Omomyc-expressing
cells may have a slower cell cycle in vivo. The presence of Omomyc
was correlated with the upregulation of GFAP and bIII-tubulin and
the downregulation of the GSC marker OLIG2 (Figs 2E–G and EV2C).
The number of migrating cells—detected by immunostaining of the
neuronal precursor migration marker DCX (doublecortin)—was
significantly reduced (Figs 2D and EV2C). An extensive proliferation
of blood vessels is a pathological feature of glioblastoma that distin-
guishes it from less aggressive gliomas. Omomyc strongly repressed
vascularization of the tumour stroma (CD31 staining in Fig 2C).
Therefore, MYC inhibition in GSCs suppresses their intrinsic tumori-
genic features but also induces cell non-autonomous changes on the
tumour microenvironment that impair blood vessel formation.
Impact on MYC genome occupancy
MYC binds DNA at E-boxes in thousands of genomic loci [3]. To
assess the consequences of Omomyc expression on MYC DNA bind-
ing, we performed chromatin immunoprecipitation with a MYC anti-
body coupled with DNA sequencing (ChIP-seq) in BT168FO cells
treated or not with Dox for 24 h (Dataset EV1). Over 12,000 MYC
peaks were detected in cells untreated with Dox: 36% localized at
RNA polymerase II (Pol II) promoters, defined as –1,000 to +100 bp
regions surrounding transcription start sites (TSSs), 37% intragenic,
and 27% intergenic. A MYC enrichment area was present in about
21% of all RefSeq promoters. A similar distribution was found in
the U87MG (U87) glioblastoma cell line that represents the bulk of
tumour cells (not shown), concordant with published data [11].
Less than half of the U87 peaks overlapped BT168 peaks, consistent
with the view that many MYC targets are cell type specific [3]. To
verify that MYC binding was indeed associated with the presence of
the E-box, we conducted an enrichment analyses of transcription
factor DNA-binding motifs in the MYC-bound regions (Table 1). In
cells untreated with Dox (Table 1, left), E-boxes were the most
significantly enriched motifs, but we also found a strong over-repre-
sentation of binding sites of other TFs (SP1, E2Fs, EGR1 and 2,
NRF1, KLF4) implicated in cell cycle progression, stemness, metabo-
lism and response to extracellular signals.
The presence of Omomyc led to a strong, genomewide attenua-
tion of MYC signals at promoters in BT168FO (Fig 3A) and U87FO
(Fig 3B) cells. The MYC molecules that were still bound to chro-
matin lost the preferential association with E-boxes and the other
motifs found in naı¨ve cells and were mainly connected with AT-rich
regions and binding motifs of other TFs (MEF2A, MEF2C and FOX
family factors) associated with neurogenesis and differentiation
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(Table 1, middle). Therefore, Omomyc appears to interfere with
proper MYC localization on the genome. MYC signal depletion at
promoters might be due to inhibition of MYC/MAX dimer formation
[17] as well as to occupancy of MYC binding sites by Omomyc [17].
To clarify this point, we performed ChIP-seqs with Flag antibodies
in cells treated or not with Dox for 24 h and compared them with
MYC ChIP-seqs in the same conditions (Fig 3A and B). As indicated
by the motif enrichment analyses of Table 1, Dox treatment led to
the appearance of Omomyc DNA binding signals, with a preference
for sequence motifs—like the E-boxes and other—also bound by
MYC. The attenuation of MYC signals around TSSs observed in Dox-
treated cells was accompanied by the appearance of Omomyc
signals in the same regions, as pointed out by heatmaps (left) and
signal profiles of gene clusters (right) in Fig 3A and B. The appear-
ance of Omomyc binding at promoters that lost MYC binding
seemed to occur globally in BT168FO cells (3A), whereas a set of
genes in U87FO cells—the bottom clusters in Fig 3B—did not
appear to gain Omomyc signal upon MYC binding loss. The patterns
of normalized MYC and Omomyc ChIP-seq signals on three well-
established and widespread MYC target genes—NCL (nucleolin),
A B
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Figure 1. Omomyc inhibits GSC proliferation, self-renewal and migration while promoting differentiation.
A Scheme of the lentiviral vector with inducible FlagOmomyc (top) and immunoblotting (bottom) of FlagOmomyc and actin loading control upon Dox treatment of
BT168FO cells for 0–48 h.
B Proliferation curves of BT168FO and BT168GFP cells upon Dox treatment for 0–96 h (n = 3; mean  SD). Viable cells were counted using a haemocytometer.
C, D Self-renewal assay upon Dox treatment. (C) Histograms showing the percentage of cells capable of re-forming a neurosphere seven days after dissociation (n = 3;
mean  SD). (D) Representative micrographs of BT168FO cell neurospheres.
E qRT–PCR of proliferation, stem cell and differentiation markers (CCND1, PTEN, SOX2, NOTCH1, NESTIN, MYC) in BT168FO cells after 48 h of Dox treatment, compared
to uninduced cells (n = 3; mean  SD). Expression levels in non-induced cells were set as 1.
F Transwell migration assay of BT168FO cells after 3 days with or without Dox (n = 3; mean  SD). 10 fields were counted per assay.
G Immunofluorescence analyses of GSC differentiation. To stimulate differentiation, BT168FO were grown as a monolayer in the presence of serum and treated with
doxycycline for up to 7 days. The upper panel displays immunofluorescence images of NESTIN, GFAP, bIII-tubulin, SOX2 and FlagOmomyc expression. FlagOmomyc
blunted SOX2 expression and decreased GFAP and NESTIN protein levels, while inducing the onset of bIII-tubulin. The lower panel shows the percentage of positive
cells for each cell marker evaluated (n = 4; mean  SD). 16 fields for each assay were examined; scale bar = 100 lm.
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ODC1 (ornithine decarboxylase) and MIR17HG (miR-17-92
microRNA cluster host gene)—in BT168FO (Fig EV3A) and U87FO
(Fig EV3B) support the view that Omomyc is enriched at target
promoter regions upon attenuation of MYC signals. It is however
unclear whether Omomyc precisely replaces MYC because Omomyc
peaks—like in one of the gene clusters of Fig 3A—have some
tendency to be more diffuse than MYC ones and the signal enrich-
ments are not always strong, possibly due to a limited efficiency of
the Flag antibody in the Flag-tagged Omomyc ChIP. The reciprocal
DNA binding pattern of MYC and Omomyc observed in the ChIP-
seqs was validated through qChIP assays on single genes, including
NCL and MIR17HG (Fig EV4). We also performed qChIP assays with
MAX antibodies in order to answer the question whether Omomyc
binds E-boxes in partnership with MAX, with which it is able to
dimerize [17]. Omomyc inhibited MAX binding to DNA (Fig EV4),
to indicate that Omomyc does not bind to DNA in a complex to
MAX, but rather as homodimer, which is its most abundant state
within cells [21].
Omomyc minimally—or not at all—influences RNA Pol II loading
at promoters and transcript elongation and affects transcription
in a subset of targets only
MYC is found at promoters of most transcriptionally active genes.
High MYC levels cause transcriptional amplification producing
increased level of transcripts, by promoting transcriptional pause
release at all active promoters; this correlated with increased levels
of elongation-associated Ser2-phosphorylated RNA Pol II (Pol II
Ser2p) as compared with initiation-associated Ser5-phosphorylated
RNA Pol II (Pol II Ser5p) [10,11]. We asked whether loss of MYC
and gain of Omomyc binding would influence Pol II loading at
promoters and transcriptional elongation, and globally affect
mRNA production. To clarify this point, we performed Pol II ChIP-
seq experiments in BT168FO and U87FO cells treated or not with
Dox for 24 h (Figs 4 and EV5), and compared the results with
RNA-sequencing data (Dataset EV2). We did not observe relevant
global changes of Pol II loading around TSSs between cells express-
ing or not Omomyc; a similar conclusion regarding TTSs (Tran-
scription Termination Sites) can be drawn from a Pol II Ser2p
ChIP-seq (Figs 4 and EV5). We tried different approaches, but only
a negligible fraction of genes showed significant enrichment
changes of either Pol II at TSSs (2% of all genes and 4% of MYC
promoter-target genes) or Pol II Ser2p at the TTSs (1% of all
genes). Also, the changes were more or less equally split between
genes with greater enrichment in −Dox and those with more
enrichment in +Dox cells. We also performed validating qChIPs
with Pol II Ser2p and Ser5p specific antibodies on single MYC
target genes (Fig 4D). Although minor changes in Pol II Ser2p and
Ser5p levels could be found in these genes, their relative ratios
remained constant upon Omomyc expression (Fig 4D), suggesting
that Omomyc does not significantly impact transcriptional pause
release. To further clarify this point, we directly investigated pause
release by measuring the RNA Polymerase II travelling ratio—
defined as in [4]—from the Pol II ChIP-seqs, in the presence or
absence of Omomyc. We found the same travelling ratio distribu-
tion reported by Rahl and co-workers [4]—which validates our
data—but minimal changes upon Omomyc expression (Fig 4E). We
think that all these data are sufficient to infer that Omomyc only
marginally affects global Pol II loading at promoters, pause release
and transcriptional elongation.
We did not detect a global correlation among loss of MYC bind-
ing, gain of Omomyc binding and decreased transcript levels. This
correlation was detectable in a subset of genes only, as exemplified
by the five genes in Fig 4: NCL, miR-17-92 (MIR17HG), OLIG2,
HDAC1 and DUSP10. They all were expressed at good levels (FPKM
> 4) in BT168FO cells and showed attenuation of MYC binding
[blue] upon Dox treatment (Fig 4B and C). Attenuation or loss of
MYC and gain of Omomyc signal (green) was accompanied by
A
B
C
D
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F
G
H
Figure 2. Reduced migration and vascularization, and increased differentiation in xenografts of Omomyc-expressing GSCs.
A–H Immunostaining of representative xenografts derived from naïve (control) and Omomyc-expressing BT168FO cells. (A–D) Flag, Ki67, CD31 and DCX (doublecortin)
immunostaining of adjacent sections in control and Omomyc xenografts. (E–G) Differentiation phenotype investigated by GFAP, bIII-tubulin, and OLIG2 staining.
(H) Immunostaining for anti-human nuclei. Representative images are shown. Scale bar = 100 lm.
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minimal changes of Pol II signals at promoters, gene bodies and
termination regions, with the exception of OLIG2 (Fig 4B). NCL,
miR-17-92 and OLIG2 displayed clearly decreased transcript levels
(Fig 4C). NCL and miR-17-92 are known to be upregulated by MYC
in a variety of cell contexts, whereas OLIG2 is a master controller of
neural stem cell behaviour whose regulation by MYC was unknown.
The correlation between decreased MYC binding and decreased
transcript level was instead absent in HDAC1 and DUSP10 (Fig 4B
and C), whose mRNA levels were unaffected or barely affected by
the attenuation of MYC signals at their promoter regions (Fig 4C).
Similar data were found in U87FO cells, in which the only signifi-
cant difference from BT168FO concerned OLIG2, which was silenced
in U87 cells and showed no MYC or Omomyc signal and no signifi-
cant Pol II binding (Fig EV5). In some instances, loss of MYC bind-
ing was even associated with transcript upregulation. An example is
PPP2R5A—encoding a regulatory subunit of protein phosphatase
2—which was upregulated about fourfold upon loss of MYC
promoter binding (not shown). Thus, decreased MYC occupancy at
promoters was not always associated with decreased transcription,
and in many cases, the transcript levels were unaffected or even
increased.
Impact on cancer stem cell transcriptome
The comparison between ChIP-seq and RNA-seq data of BT168FO
cells (Datasets EV1 and EV2) showed that 94% of MYC promoter-
target genes were transcribed (FPKM > 0) in cells untreated with
Dox; similar data were obtained in U87FO cells. Therefore, tran-
scriptionally active promoters in glioblastoma cells had a strong
preference for MYC, similarly to active promoters—as well as
enhancers—in other cell types [5,10,11]. Promoter occupancy by
MYC increased together with transcript level (Fig 5A, black), con-
firming the correlation between increased transcription and
increased MYC promoter occupancy [5,11]. Upon Dox treatment,
promoter occupancy by MYC decreased (see also Fig 3) and no
longer grew together with gene expression level (Fig 5A, blue).
From RNA-seq transcript levels (FPKM) in Dox-treated and
untreated cells, we computed the expression changes of MYC-
bound genes, subdivided into promoter-targets presenting a MYC
peak at their promoter, intragenic targets with a peak on gene
body and intergenic targets with a peak within a 50-kb range from
the TSS compatible with the location of an enhancer or super-
enhancer influencing gene transcription (Fig 5B). The mean
Table 1. Motif enrichment analysis of Myc- and Omomyc-bound DNA sequences.
BT168FO no Dox BT168FO +Dox BT168FO +Dox
Myc-bound
motif ID G_P VALUE
Myc-bound
motif ID G_P VALUE
Omomyc-bound
motif ID G_P VALUE
Myc MA0147.1 0 TBP MA0108.1 7.16E-80 ZEB1 MA0103.1 4.82E-189
Mycn MA0104.2 0 MEF2A MA0052.1 1.56E-78 ZNF263 MA0528.1 2.34E-91
MYC::MAX MA0059.1 0 MEF2C MA0497.1 3.21E-78 PLAG1 MA0163.1 1.64E-70
USF1 MA0093.1 0 FOXL1 MA0033.1 1.54E-73 Klf4 MA0039.1 7.53E-43
Arnt MA0004.1 0 Foxd3 MA0041.1 1.62E-67 Mycn MA0104.1 2.03E-41
HIF1A::ARNT MA0259.1 0 ARID3A MA0151.1 6.43E-65 MZF1_5-13 MA0057.1 8.20E-35
Arnt::Ahr MA0006.1 0 Lhx3 MA0135.1 1.17E-56 YY1 MA0095.1 8.62E-35
NRF1 MA0506.1 0 Prrx2 MA0075.1 6.80E-54 NR2C2 MA0504.1 3.39E-34
ZBTB33 MA0527.1 0 FOXP1 MA0481.1 1.67E-44 E2F6 MA0471.1 2.89E-31
EGR2 MA0472.1 0 CDX2 MA0465.1 8.95E-43 SP1 MA0079.2 1.05E-29
TFAP2A MA0003.1 0 Pax4 MA0068.1 4.07E-42 Spz1 MA0111.1 1.79E-29
E2F3 MA0469.1 0 Nkx2-5 MA0063.1 8.36E-40 Arnt MA0004.1 1.63E-28
E2F1 MA0024.2 0 Mecom MA0029.1 9.81E-40 Myc MA0147.2 4.79E-27
PLAG1 MA0163.1 0 ZEB1 MA0103.1 2.53E-39 EWSR1-FLI1 MA0149.1 6.62E-27
E2F4 MA0470.1 0 POU2F2 MA0507.1 6.76E-39 Zfx MA0146.2 7.16E-24
NFKB1 MA0105.2 0 FOXI1 MA0042.1 1.39E-38 USF1 MA0093.1 7.27E-24
Zfx MA0146.2 0 IRF1 MA0050.2 1.24E-36 PPARG::RXRA MA0065.2 5.81E-22
E2F6 MA0471.1 0 HNF1A MA0046.1 1.16E-34 MAX MA0058.2 6.88E-22
EGR1 MA0162.2 0 Pdx1 MA0132.1 1.80E-34 MZF1_1-4 MA0056.1 1.21E-19
SP1 MA0079.3 0 SRY MA0084.1 1.44E-31 SP2 MA0516.1 1.27E-18
Klf4 MA0039.2 0 Pou5fl::Sox2 MA0142.1 2.52E-26 PAX5 MA0014.2 1.86E-18
SP2 MA0516.1 0 Foxq1 MA0040.1 9.67E-26 E2F3 MA0469.1 2.08E-16
KLF5 MA0599.1 0 Sox2 MA0143.2 1.45E-25 Bhlhe40 MA0464.1 1.50E-15
Motif enrichment calculated by PscanChIP [64] from Myc and Omomyc ChIP-seq data in BT168FO cells, treated or not with doxycycline for 24 h. Motif IDs are
from Jaspar database (http://jaspar.binf.ku.dk/).
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AB
Figure 3. Loss of MYC and appearance of Omomyc ChIP-seq signals around TSSs of MYC promoter-target genes.
A, B Seqminer heatmaps of MYC and Omomyc levels around TSSs of all MYC promoter-target genes in BT168FO (A) and U87FO (B) cells, treated or not with Dox for
24 h. TSS regions are ranked by decreasing MYC occupancy in untreated cells. Each row shows the  5-kb region centred on TSSs. Colour scaled intensities are in
units of tags per 50 bp. The plots adjacent to each heatmap depict MYC and Omomyc binding patterns at genes in the two gene clusters denoted by arrows, in
cells treated or not with Dox.
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expression fold changes were low—about 20–30%—but similar at
all transcript expression levels, and were comparable between up
and downregulated transcripts (Fig 5B). A similar distribution was
observed in non-target genes as well (Fig 5C). Expression changes
were clearly shifted towards negative values (downregulation)
only in the most highly expressed MYC targets (Fig 5B). Tran-
scripts not so highly expressed represented the large majority of
the genes and were comparably distributed between up- and
downregulated.
We focused on the transcripts most significantly modulated upon
MYC inhibition. From RNA-seq data for each time point of Dox
treatment (4–48 h) versus untreated cells (Dataset EV2), we defined
the significantly modulated transcripts through CuffDiff2, as well as
by applying a fold change cut-off (log2FC ≥ 0.25 or ≤ 0.25) and
requiring a P-value threshold. We also assessed the significantly
modulated MYC targets by Gene Set Enrichment Analysis (GSEA,
www.broadinstitute.org/gsea/). The outcomes of these approaches
were coherent. The average fold changes of all classes of signifi-
cantly modulated transcripts were similar (Fig 5C). The significantly
modulated MYC promoter-targets (Fig 5D) presented a strong linear
correlation (R = 0.94–0.99) between expression in the presence of
Omomyc (24 h Dox) and in untreated cells. Again, only the more
highly expressed target transcripts were preferentially downregu-
lated (Fig 5C and D). In conclusion, MYC inhibition influenced the
expression level of several thousand transcripts, a relevant fraction
of which displayed a MYC peak at promoter, gene body or inter-
genic region. Only the more highly expressed genes tended to be
repressed upon MYC inhibition. The average transcript fold change
was very similar for up- and downregulated transcripts.
To clarify the function of Omomyc-modulated genes, we looked
for overlaps between genes—both MYC targets and not—
modulated by Omomyc in BT168FO cells at 4, 8, 16, 24 and 48 h
of Dox treatment and the hallmark gene sets of the Molecular
Signature Database (MSigDB, at Broadinstitute.org). We found
highly significant overlaps with gene sets defining epithelial–
mesenchymal transition, TNFA signalling via NF-jB, hypoxia,
oxidative phosphorylation, angiogenesis, inflammatory response,
p53 signalling, beta-catenin signalling, mitotic spindle, UV
response, E2F targets, glycolysis, NOTCH signalling, MTORC1
signalling, DNA repair, KRAS signalling (Dataset EV3 and
Appendix Fig S1). This suggests a broad role in regulating stemlike
cell and cancer relevant pathways.
Impact on key controllers of tumorigenesis and glioblastoma
stem cell identity
All this indicates that MYC influences the entire gene expression
network but does not explain how the expression changes of
thousands of genes may have a tumour suppression-specific effect
that hits practically all cancer stem cell features. This might be
explained if MYC inhibition by Omomyc especially acted on the
control points of gene expression programmes that determine
cancer stem cell behaviour, because even small changes in master
regulator expression may affect large gene sets and lead to strong
phenotypic changes. To clarify this aspect, we investigated the
expression of a set of genes selected for being related to such
control points according to literature data. We took into account
universal MYC targets mediating its tumorigenic properties, tran-
scription factors and other molecules involved in tumorigenesis
and tumour suppression in various tumours including glioblas-
toma, and cell-specific factors that maintain the glioblastoma
cancer stem cell phenotype. Among the universal MYC targets,
we examined CCND1, CDK6 and NCL—which are implicated in
cell proliferation and cell growth control and have a role in
glioblastoma [35–37]—and miR-17-92. They were all strongly
downregulated by Omomyc (Fig 6A). miR-17-92 maintains a
neoplastic state by suppressing the expression of chromatin
regulatory genes like Sin3b (cellular senescence regulator), Hbp1
(neurogenesis modulator) and Btg1 (neuronal precursor regulator)
[9]. Omomyc also strongly repressed FOS, JUN and ID4 transcripts
encoding oncogenic transcription factors that have a role in
glioblastoma. On the contrary, it upregulated the tumour-suppressive
phosphatases PTEN and PPP2R5A (protein phosphatase A regula-
tory subunit), a controller of mitotic progression, and the long
non-coding RNA (lncRNA) MIAT/GOMAFU involved in neurogenic
commitment and differentiation [38]. All these genes were more
strongly regulated than average; PPP2R5A and MIAT were among
the most strongly upregulated transcripts. We also considered a
set of genes—the dual specificity protein kinase phosphatases
(DUSPs), which control MAP kinase signalling—chosen with no
bias regarding literature data. Omomyc can affect components of this
family in either direction (Fig 6A). Notably, Omomyc strongly
affected the expression of DUSPs 4, 5, 6, which have been implicated
in GBM [39].
The gene regulatory programmes responsible for cell identity are
controlled by a limited set of master transcription factors that vary
among the different cell types. GSCs present a set of 19 TFs that are
specifically active and include a core subset of only four of them
that are sufficient for maintaining GSC phenotypes in vitro and
in vivo; the four core TFs target a set of 325 genes [40]. By Gene Set
Enrichment Analysis, we found that the set of 19 GSC-specific TFs
was significantly associated with repression in response to Omomyc
(Fig 6A). Notably, three of the four core TFs—POU3F2, SOX2 and
OLIG2—were MYC targets and were scored downregulated by GSEA
(Fig 6A; Datasets EV1 and EV2). Consistently, Omomyc repressed
both components of the KDM1A (LSD1) lysine-specific histone
◀ Figure 4. Transcription at some MYC target promoters is modulated by Omomyc.A Heatmap of RNA Pol II levels around TSSs of MYC promoter-target genes in BT168FO cells, treated or not with Dox for 24 h. TSS regions are ranked by decreasing
MYC occupancy in untreated cells. Each row shows the  5-kb region centred on TSSs. Colour scaled intensities are in tags/50 bp.
B Tracks of Pol II binding signals (ChIP-seq) at NCL, miR-17-92, OLIG2, HDAC1 and DUSP10 genes in BT168FO cells treated or not with Dox for 24 h. The y-axis shows
Pol II binding signals as tags/500 bp per million reads. The x-axis displays genomic positions; introns as lines, exons as boxes. Arrowheads denote direction of
transcription. Blue and green bars denote the presence of MYC or Omomyc peaks, respectively. Grey boxes are TSS regions.
C Transcript levels (FPKM from RNA-seq data) in BT168FO cells of the genes shown in (B). Data are means of three independent biological replicates.
D Ratio between fold enrichments (specific antibody/IgG signal) derived from qChIPs of Pol II-Ser2p and Pol II-Ser5p (n = 3; mean  SD).
E RNA Polymerase II travelling ratio distribution from the Pol II ChIP-seqs, in the presence or absence of Dox.
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demethylase/RCOR2 complex, which is a key OLIG2 effector in
GSCs [40,41] (Fig 6A); both genes were MYC targets as well.
Finally, the set of 325 targets of the core TFs was associated with
repression by Omomyc (Fig 6B and C). In conclusion, MYC inhibi-
tion strongly influenced the transcript levels of key TFs responsible
of GSC identity, of their targets and of chromatin modifiers involved
in their activity.
Moreover, by interrogating the Molecular Signature Database we
observed that Omomyc expression was negatively correlated with
the proneural gene expression signature that is associated with resis-
tance to current therapies for glioblastoma [42; not shown]. We
asked whether MYC-modulated gene signatures obtained in other cell
types were significantly enriched among the transcripts modulated
by Omomyc in GSCs. By GSEA software, we found that several signa-
tures of MYC-upregulated genes present in MSigDB hallmark gene
sets were associated with downregulation by Omomyc in GSCs, while
the opposite was true for the MYC-downregulated signatures (Fig 6B
and C, Dataset EV3 and Appendix Fig S1). Therefore, Omomyc
affected genes commonly modulated by MYC in other contexts.
microRNAs modulated upon MYC inhibition affect basic features
of glioblastoma cells
Some microRNAs are known to mediate MYC function and to be
involved in glioblastoma [43–45]. To identify those responding to
MYC inhibition, we analysed through qRT–PCR arrays the miR
expression profiles of two GSC cell types, BT168FO and BT275FO.
We selected miRs that were either upregulated ≥ 1.5-fold or down-
regulated ≤ 0.5-fold in both: 21 miRs were downregulated and 41
upregulated (Table 2; Dataset EV4). One third of the downregulated
miRs were members of the miR-17-92 cluster and the cognate clus-
ter on chromosome X. The upregulated ones included the tumour-
suppressive microRNAs miR-15a and miR-16, as well as miR-23a—
an inhibitor of glutaminase, which restrains glutamate consumption
A
C D
B
Figure 5. Omomyc-dependent gene expression changes.
A Promoter occupancy by MYC correlates with transcript levels in cells untreated with doxycycline (black line). In doxycycline-treated cells promoter occupancy by MYC
is lower, and no longer increases together with transcript levels. The scatter plot displays MYC ChIP-seq reads at promoters (1,000, +100 regions with respect to
TSS) in BT168FO cells: untreated (black) or upon 48 h of Dox treatment (blue) versus transcript levels (FPKM from RNA-seq data).
B Distribution of transcript level differences (D FPKM) of single genes classified as promoter-targets (green), intragenic-targets (blue), intergenic-targets (red) in Dox-
treated (24 h) versus untreated cells, plotted against expression in untreated cells (n = 3). D FPKM = FPKM_24 h Dox – FPKM_no Dox.
C The table first row shows the number of genes significantly up- or downregulated at 24 h of Dox treatment, subdivided into promoter-, intragenic-, intergenic-
targets ( 50 kbp from TSS) and the rest. The following rows depict—for each gene class—mean (average) values of FPKM in cells treated or not with Dox for 24 h
and the corresponding D FPKM and fold change (FC). Data are from three independent biological replicates.
D Transcript level distribution of MYC promoter-targets significantly down (red dots) or up (green dots) modulated in cells treated with Dox for 24 h versus untreated
cells. Transcript levels, expressed as FPKM, represent averages of three independent experiments.
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as energy source, encoded by two clusters repressed by MYC
[6,46,47]. We performed pathway analysis of presumptive targets of
the Omomyc-modulated miRs by means of DIANA-miRPath [48]
(Fig 7A). The highest ranking pathways (pathways in cancer, cell
cycle, glioma and others) were consistent with the notion that
Omomyc may influence GSC properties via miRs. Notably, targets of
upregulated miRs had a strong correlation with terms such as DNA
replication, Ribosome, Wnt signalling, indicative of a role in repress-
ing glioblastoma cell growth [49]. The downregulated miRs affected
focal adhesion, suggesting that their downregulation may contribute
to restrain cancer stem cell migration. We then interrogated the
TCGA (The Cancer Genome Atlas; cancergenome.nih.gov) database
in order to assess the potential role of miRs modulated by Omomyc
in clinical cases of glioblastoma. We asked whether they presented
expression differences between human glioblastoma and normal
brain samples. Nine of the Omomyc-downregulated miRs were
enriched in the set of miRs overexpressed in GBM (Table EV1); two
(miR-299-5p and miR-107) showed the opposite behaviour, and the
others were not modulated in the TCGA data set. Among the
Omomyc-induced miRs, seven were underexpressed in GBM versus
normal brain, whereas twelve were overexpressed, suggesting that
the latter may have a different role in GSCs as compared with the
bulk of the tumour mass. Thus, a large fraction of the miRs
repressed by Omomyc in GSCs and a smaller part of the induced
ones may be controlled by MYC and relevant for glioblastoma.
Among the upregulated miRs, we focused on miR-146b and the
miR-200a-200b-429 cluster because the latter can target ZEB1 [50]—
a controller of the epithelial to mesenchymal transition (EMT) and a
promoter of invasion and therapy resistance in glioblastoma [51]—
while miR-146b can target the EGF receptor (EGFR), whose over-
expression is a hallmark of glioblastoma [52]. ZEB1 and EGFR
decreased upon Omomyc induction in GSCs (Fig 7B), indicating that
they may be inhibited by these miRs. To prove this, we transfected
U87FO cells with LNA oligos targeting miR-200a-200b-429 and miR-
146b. Expression of miR-146b and the miR-200 cluster rose upon
Omomyc induction in untransfected cells, EGFR and ZEB1 amounts
were reduced, and cell growth dropped (Fig 7C, D, and F). The pres-
ence of the LNA oligos attenuated the decrease of EGFR and ZEB1
(Fig 7E) and partly rescued the growth inhibition (Fig 7F). The
strongest effect was obtained by combining anti-miR-200 and anti-
miR-146b. As ZEB1 is involved in the migratory potential of
glioblastoma cells [51], we performed transwell migration assays
(Fig 7G) and found that Omomyc induction nearly halved the
migrating cell number; consistently, miR-200a-200b-429 depletion
led to partial recovery of the migratory potential. These data suggest
that at least part of the anti-migratory and anti-proliferative effects
of Omomyc may be exerted post-transcriptionally, through the
increased expression of miR-146b and the miR-200 cluster.
In conclusion, Omomyc especially affected the expression of key
regulators of tumorigenic features and cancer stem cell properties
by repressing genes and non-coding RNAs positively correlated with
tumorigenic properties and cancer stem cell identity, whereas the
Figure 6. Omomyc resets gene expression programmes of glioblastoma stemlike cells.
A RNA-seq expression values of select genes in BT168FO GSCs along a 48-h time course of Omomyc induction (n = 3 independent biological replicates). The block on
the left represents DUSP (dual specificity phosphatase) family genes. The middle block contains transcription factors (TFs): the upper thirteen (ASCL1–SALL1) are GSC-
specific and the remaining ones are oncogenic. The right block contains genes, including well-known MYC targets, with functions in proliferation, neurodifferentiation
and gliomagenesis. The first column of each block represents the average expression (log2FPKM) in untreated cells (0 h) in the colour scale illustrated by the lower
bar: violet indicates low and blue high expression. The other columns depict relative expression versus untreated cells (average log2FC) at different times (8–48 h) of
Dox treatment, according to the scale shown by the upper bar: red indicating low and green high expression. The table in the upper left summarizes the GSEA score
of the set 19 GSC-specific transcription factors [40], showing a significant downregulation by Omomyc.
B Enrichment plots obtained by GSEA (Gene Set Enrichment Analysis) of RNA-seq data from BT168FO cells. (Left) Genes downregulated by Omomyc in BT168FO identify
the set of genes targeted by the GSC core TFs [40]. (Middle) Omomyc-downregulated genes identify a gene set upregulated by MYC in cancer cells [66]. (Right) Genes
upregulated by Omomyc identify genes downregulated in small cell lung cancers carrying MYC amplification [2].
C The tables show enrichment analyses of various examples of MYC-regulated gene sets [67–70] present in MSigDB (http://www.broadinstitute.org/gsea/msigdb) and of
the gene set targeted by the GSC core TFs [40], versus genes repressed (left table) or induced (right table) by Omomyc in the RNA-seq data set.
Data information: NES, normalized enrichment score; FDR, false discovery rate.
Table 2. Omomyc-modulated microRNAs.
Upregulated Downregulated
miR-125a-5p miR-23a-3p miR-107
miR-126 miR-24-1-5p # miR-18a-5p; miR-19a-3p;
miR-19b-3p; miR-20a-5p #
miR-132; miR-212 miR-28-3p miR-18b-5p; miR-20b-5p;
miR-363-3p
miR-138 miR-331-3p miR-193a-5p
miR-139-5p miR-320 miR-199b-3p
miR-140-3p miR-339-3p miR-299-5p; miR-494-3p
miR-146b-5p miR-342-3p miR-337-5p
miR-150-5p miR-345 miR-34a-5p
miR-152 miR-449b-5p miR-367
miR-15a-5p; miR-16-5p miR-450a-5p miR-519a-3p
miR-182-5p; miR-183-5p miR-454-3p miR-542-3p
miR-186-5p miR-483-5p miR-597-3p
miR-191-5p miR-484 miR-618
miR-192-5p; miR-194-5p miR-545-3p miR-629-5p
miR-193b-3p miR-574-3p miR-652-3p
miR-196b-5p # miR-616-3p
miR-200a-3p; miR-429 # miR-628-5p
miR-210 miR-708-5p
Results of qRT–PCR array of microRNA expression upon Dox treatment of
BT275FO and BT168FO glioblastoma stem cells. Only those microRNAs that were
consistently modulated in both are shown. Upregulated: ≥ 1.5-fold compared to
uninduced control. Downregulated: ≤ 0.5-fold versus control. MicroRNAs known
to be clustered in the genome and consistently modulated are indicated
together. The symbol # indicates microRNAs or microRNA clusters whose
precursors were found consistently modulated in our RNA-seq data.
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contrary was true for genes promoting differentiation or tumour
suppression. This supports the hypothesis that MYC may act on the
gene expression programme control nodes.
Discussion
We report the broad impact of the MYC inhibitor Omomyc on
glioblastoma stem cell behaviour in vitro and in vivo (Figs 1 and 2).
This appears to relate to changes in MYC binding to DNA. MYC
binds to E-boxes at regions around the transcription start sites of
thousands of genes in GSCs (Fig 3). The MYC-bound regions are
also enriched in binding sites for other transcription factors such as
E2F, EGR1, NRF1 and KLF4 (Table 1), suggesting that MYC may
cooperate with these proteins—particularly with E2F as indicated by
Appendix Fig S1 and Dataset EV3—to regulate subsets of genes
involved in different aspects of GSC behaviour. Omomyc clearly
disrupts proper MYC localization on the genome and binds to the
MYC-bound regions, presumably as homodimer (Figs 3, EV3 and
EV4). In cells expressing Omomyc, there is less MYC and more
Omomyc around TSSs (Fig 3), suggesting that Omomyc may replace
MYC at promoters. However, this is not yet certain, as Omomyc
peaks tend to be more diffuse and noisy.
The E-boxes bound by MYC/MAX complexes are also targets of
the extended MYC network complexes: complexes between MAX or
MLX, and MXDs, ChREBP, and MONDOA [53]. By occupying such
E-boxes (Table 1 and Figs EV3 and EV4), Omomyc may affect the
whole network and influence differentiation and metabolic
processes important for cancer cells [53]. Moreover, it might
prevent a strong downregulation of MYC target genes, by inhibiting
MXD transcriptional repressor DNA binding. Consistent with this
possibility, the transcripts modulated by Omomyc are on the aver-
age only weakly repressed (Fig 5).
It is well known that a deregulated MYC alters the levels of many
transcripts, by either upregulation or downregulation [3]. MYC
overexpression leads to increased promoter and enhancer occu-
pancy and transcriptional amplification [5,10–12]. Accordingly,
genes more highly expressed tend to have more MYC at promoters
(Fig 5A). Surprisingly, loss of MYC binding at promoters minimally
affected Pol II binding (Figs 4 and EV5) and led to decreased tran-
script amounts in a subset of targets only (Figs 4 and 5). While
Omomyc attenuated a large number of transcripts—as expected for
a MYC inhibitor—it also enhanced a similar number, the average
extents of up- and downregulation being comparable (Fig 5B–D).
The finding that the more highly expressed targets clearly tend to be
downregulated by Omomyc (Fig 5) is in good accordance with the
model viewing MYC as an exponential-type, rather than linear,
amplifier that operates better on highly expressed versus weakly
expressed transcripts [5,54]. While a nonlinear transcriptional
amplification of the cancer cell expression programme caused by
elevated MYC levels may elucidate tumorigenicity by MYC
[10,11,54], it is still debated whether it represents its key oncogenic
feature. It is also unclear that a deregulated MYC necessarily needs
to be strongly overexpressed in order to be tumorigenic [1,3,5]. This
attractive model came out difficult to either prove or disprove in the
absence of a better definition of the MYC-amplifier transfer function
[5]. If MYC simply amplifies already expressed genes, it becomes
difficult to account for groups of genes repressed by MYC [55]:
repression is thus believed to be only apparent, due a change in the
relative ratio of amplified transcripts [5]. It is uncertain that strongly
increasing MYC would affect and reveal targets that were already
repressed at low or moderate MYC levels since they would presum-
ably continue to be repressed, with little change of their transcript
levels. The levels of repressed targets are instead expected to
increase upon MYC inhibition. We find that transcripts of many
genes have an enhanced expression upon loss or attenuation of
MYC binding to their promoters (Fig 5B–D) and that known MYC
targets do not seem to respond to MYC inhibition by Omomyc more
strongly when their transcript levels are higher (Fig 4C), as would
be expected according to a strict amplification model [5]. So, while
the amplifier model is important and has high heuristic value, it is
still undetermined whether it may give a full picture of MYC role in
gene expression and cancer. The transcriptional outcome of MYC
action might thus involve additional players such as lncRNAs or
chromatin modifiers like the MYC-associated methylosome (histone
arginine methylase complex) and the modifications it triggers [56].
Omomyc might influence composition and activity of MYC effector-
complexes associated with chromatin and participate itself in such
complexes. Its action appears to involve as well effects different
from those caused by the simple MYC inhibition—for example, the
histone modification H4R3me2s, enhanced by both MYC and
Omomyc [56], the inhibition of DNA binding by MAX and partners,
and possibly other.
The relative levels of MYC-modulated transcripts appear to be
rebalanced in the presence of Omomyc, as indicated by known target
gene signatures: those commonly enhanced by MYC are repressed,
Figure 7. Omomyc-modulated microRNAs in glioblastoma stemlike cells.
A List of KEGG pathways significantly enriched in the genes targeted by miRs up- or downregulated upon Omomyc induction (Table 2). The number of affected genes
and the number of miRs targeting them are indicated for each pathway together with merged P-values computed as in [48], denoting the probability that the
examined pathway is not enriched with gene targets of at least one selected microRNA.
B Immunoblots of EGFR, ZEB1 and GAPDH loading control expression in BT168FO and BT275FO after 2 days with (+) or without () Dox. Representative images are
shown.
C qRT–PCR expression analysis of selected miRs in U87FO cells grown 48 h in the presence (+) or absence () of Dox (n = 3; mean  SD). Expression levels were
normalized using U6 RNA as control. Expression levels in non-induced cells were set as 1.
D EGFR, ZEB1 and GAPDH immunoblots in the same cells as in panel (C). Representative images are shown.
E EGFR, ZEB1 and GAPDH immunoblots in uninduced U87FO cells () and in cells transfected with LNA oligos targeting miR-200a-200b-429 (LNA 200) and miR-146b
(LNA 146b), or with a non-targeting LNA (LNA C), and induced with Dox for 48 h (+Dox). Representative images are shown.
F MTS cell proliferation assay of uninduced or Dox-induced U87FO cells, transfected with either a non-targeting LNA (LNA C), or LNA oligos targeting the miR-200a-
200b-429 cluster (LNA 200), miR-146b (LNA 146b), or both (LNAmix) and analysed at 24, 48 and 72 h (n = 3; mean  SD).
G Migration assay of U87FO cells transfected with non-targeting control LNA oligos (LNA C) or with LNA oligos targeting miR-200a-200b-429 (LNA 200); cells were
either untreated () or treated with Dox for 24 h (+Dox); (n = 3; mean  SD).
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and vice versa (Fig 6, Appendix Fig S1, Dataset EV3). Consistently
with this concept, mRNAs of genes promoting stemness and prolifer-
ation are downregulated, while those inhibiting growth, migration,
angiogenesis or promoting differentiation are upregulated. This
conclusion is confirmed by the microRNA expression profile: MYC-
upregulated miRs (miR-17-92 and miR-106a/363 clusters) are
decreased upon MYC inhibition whereas MYC-downregulated miRs
(miR-15a, -16, -23a and -150) are increased (Table 2 and Dataset
EV4). Omomyc inhibits the expression of miRs known to be pro-
oncogenic in glioblastoma, while increasing expression of tumour-
suppressive ones (Tables 2 and EV1, Fig 7). ZEB1 repression by
miRs upregulated by Omomyc (miR-200a/-429) is accompanied by a
reduction in cell proliferation and migration (Fig 7), and it is particu-
larly interesting since ZEB1 is a key mediator of mesenchymal trans-
differentiation in glioblastoma, associated with tumour invasion
[57]. Notably, MYC inhibition leads to repression of core transcrip-
tion factors sufficient to determine GSC identity [40]. These findings
indicate that MYC may largely rule the cancer stem cell phenotype
simply by controlling the levels of a small set of transcripts like those
encoding the core transcription factors and non-coding RNAs such as
miR-200, miR-23a and miR-17-92 that maintain a neoplastic state. It
is a possibility deserving further investigation.
Our data cannot be fully explained by either of the two current
models depicting MYC as a universal, nonlinear amplifier or a target
gene-specific modulator [5,55]. The highly pleiotropic action and
endless number of MYC-regulated genes in different tissues,
together with the finding that coding genes and non-coding RNAs
defining cancer phenotype and stem cell identity are among the
most significantly affected by MYC inhibition, suggest to us a some-
what different view that may include both models. In both normal
and cancerous cells, MYC might function to stabilize the nodes of
the active gene expression programmes, established by master tran-
scription factors (activators or repressors) that are different from
MYC and control large sets of genes. Such programmes may be
active in a variety of cell types if they control basic functions such
as metabolism and protein synthesis, or may be cell type specific
like those involved in stem cell reprogramming and cell identity
control. The programmes that determine cell identity are controlled
by chromatin structures like super-enhancers and super-enhancer
domains that drive the expression of core TFs and their target genes
[58,59]. This suggests the possibility that MYC may directly target—
via protein- and RNA-mediated interactions—such structures
involved in maintaining the cellular status quo. MYC needs to be
finely regulated to allow cell flexibility. The deregulated or over-
expressed MYC present in cancer cells would tighten the nodes
controlling their phenotype and make it hard to escape the tumori-
genic condition. Inhibition of MYC expression or function, for exam-
ple through Omomyc, may loosen such nodes and promote
expression changes of master genes responsible of cancer cell beha-
viour. This may facilitate a switch of programme, by enhancing the
response to stimuli promoting differentiation and restraining tumori-
genic features such as migration and vascularization. Consistently,
MYC inhibition by Omomyc enables GSCs to better differentiate
in vitro, provided that an appropriate stimulus—like serum in the
culture medium—is present.
Our in vivo data indicate that MYC is required for tumour forma-
tion by glioblastoma stemlike cells, but did not address whether it is
also required for GBM maintenance. The in vitro data point at some
effector mechanisms that may represent vulnerability points in the
glioblastoma stem cell control circuit. One is MYC binding to
E-boxes, which might be targeted by sequence-specific inhibitors,
possibly reproducing much of the Omomyc action. Others include
microRNAs such as miR -17/92, -200a/-429, -146b and -23a [46], the
lncRNA MIAT, ZEB1, chromatin regulators like SIN3B and the
histone demethylase LSD1/RCOR2 complex [41], the phosphatase
PPP2R5A, the core TFs and the machinery that sustains their expres-
sion. It remains to be determined whether—as it seems likely—the
pervasive oncosuppressive effect of MYC inhibition on GSCs may be
generalized to cancer stem cells from other tumours. It is improbable
that the broad impact of MYC inhibition may be fully reproduced by
targeting other molecules. This increases the interest of Omomyc as
potential therapeutic agent. It may be interesting to assess direct MYC
inhibition by Omomyc and these other opportunities in clinical cases.
Materials and Methods
Cell culture and treatments
Our GSC model was previously described [28]. GSCs were grown as
neurospheres in serum-free medium, except for differentiation
assays. Cell proliferation was estimated by seeding GSCs in six-well
plates (2 × 104 cells/well) and counting cells daily: the cell suspen-
sion was thoroughly homogenized with a micropipette and aliquots
of 10 ll were used for counting on a haemocytometer (Bright-Line;
Hausser Scientific, Horsham, PA) in combination with the trypan
blue dye. Team of two individuals counted triplicate samples from
three identical sample sets. For self-renewal, GSCs were seeded in
96-well plates at 100 cells/well. The neurosphere number was
counted after 7 days and plotted against the number of cells seeded;
team of two individuals counted triplicate samples from three identi-
cal sample sets. In vitro migration was assayed by Transwell-96
system (BD Bioscience). After 24 h, migrated cells were stained with
crystal violet solubilized with 10% acetic acid and 10 fields were
counted per assay. For differentiation, cells were cultured and
treated as described [28].
The human glioblastoma U87MG cell line was purchased from
ATCC and checked for being mycoplasma-free; cells were cultured
in DMEM supplemented with 10% foetal bovine serum. Cell growth
rate was determined by Promega CellTiter Aqueous assay with MTS
tetrazolium [60]. We performed transfections by Lipofectamine
2000 [Invitrogen], using LNA oligos (Exiqon) as recommended by
the manufacturer.
Cells harbouring a doxycycline-inducible FlagOmomyc were
obtained by lentiviral infection. They were treated with 0.25 lg/ml
doxycycline (Sigma) to induce Omomyc.
Viral vectors and infections
The lentiviral plasmid pSLIK-FO was constructed by Gateway
cloning (Life Technologies). A FlagOmomyc insert was amplified by
PCR with primers introducing 50KpnI and 30XhoI restriction sites.
The KpnI–XhoI fragment was purified and cloned in the entry vector
pEN_TTmcs (courtesy of Debbie Burkhart) downstream of TRE-tight
promoter. The TRE-tight promoter/FlagOmomyc construct was
subcloned into pSLIK-Hygro (Addgene #25737) co-expressing a
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hygromycin resistance gene and Tet-transactivator rtTA3. Lenti-
viruses were prepared by co-transfecting HEK293T cells with pSLIK-
FlagOmomyc and packaging plasmids PLP1, PLP2 and pMD VSV-G.
Viral particles were purified by centrifugation and used for infection
in the presence of 4 lg/ml polybrene. Cells were selected with
50–200 lg/ml hygromycin B (Sigma).
Tumorigenicity assays
Neurospheres were injected into mouse brain after mechanical
dissociation to single cells. Two randomly selected groups of
6-week-old female nude mice (CD-1 Nude Mouse; Crl:CD1-Foxn1nu,
Charles River) were injected with 100,000 control or Omomyc
neurospheres in 2 ll PBS (n = 7/group/cell line for survival,
n = 3/group/cell line for histological studies). The coordinates, with
respect to the bregma, were 0.7 mm post, 3 mm left lateral, 3.5 mm
deep and within the nucleus caudatum. Omomyc expression was
induced by administering to mice 625 mg/kg Dox-containing food
pellets. Cumulative survival curves were constructed by the
Kaplan–Meier method (MedCalc 12.7).
Ethical statement for animal studies
All animal studies were performed in accordance with ARRIVE
guidelines and following the three Rs rule of Replacement, Reduc-
tion and Refinement principles. Mice were monitored every day and
euthanized when suffering, in accordance with the current direc-
tives of the Campus animal IFOM-IEO house facility and the Italian
Ministry of Health. Animal experiments were performed in accor-
dance with the Italian Principle of Laboratory Animal Care (D. Lgs.
26/2014) and European Communities Council Directives (86/609/
EEC and 2010/63/UE).
Immunofluorescence, histological analysis
and immunohistochemistry
For immunofluorescence, cells were processed as described [21]
with GFAP (04-1031; Millipore), Nestin (ABD69; Millipore), SOX2
(MAB4343; Millipore), bIII-tubulin (18207; Abcam) and Flag (Sigma
#F1804) antibodies. Images were captured with an Axioplan micro-
scope (Zeiss) and analysed by RSImage (Photometrics). Secondary
antibodies were rabbit Alexa Fluor 555 (#A-21428) and mouse Alexa
Fluor 488 (#A-11001; Life Technologies). For histology and
immunohistochemistry of xenografts, brains were carefully
removed, post-fixed in 4% paraformaldehyde and embedded in
paraffin. 4 lm-thick sections were dissected using a microtome. The
paraffin was removed using xylene, and the sections were rehy-
drated in graded alcohol. Antigen retrieval was carried out with
preheated target retrieval solution (pH 6.0), and the primary anti-
bodies were incubated overnight. Ki67 (1:50; BD Bioscience), DCX
(1:100; Abcam), Flag (1:500, Sigma), GFAP (1:100, DAKO), bIII-
tubulin (1:100, Abcam), human nuclei (1:150, Millipore), OLIG2
(1:100, Proteintech) antibodies were used. Bright field microscopy
combined with immunostaining was performed by rat-on-mouse
HRP-Polymer Kit (Biocare Medical). Tumour sections were stained
with haematoxylin and eosin to assess tumour growth. Tumour
slides were read independently by two different investigators operat-
ing blindly.
RNA isolation, qRT–PCR and miR profiling
Total RNA was isolated by TRIzol (Invitrogen). For microRNA pro-
filing, RNA was reverse-transcribed by using MegaplexTM RT
primers, cDNA products were loaded onto TaqMan OpenArray
MicroRNA Panels, and PCR was carried out using the manufac-
turer’s instructions (Life Technologies). Results were analysed by
RQ Manager 1.2.1 (Applied Biosystems). MiRs were subjected to
qPCR by TaqMan miR probes (Life Technologies) as described [61].
For single mRNA analysis, RNA was reverse-transcribed by M-MLV
RT (Invitrogen); qPCR was performed using the SYBR Green select
master mix (Life Technologies). Primers: CCND1: FW gaagatcgtcgcc
acctg, REV gacctcctcctcgcacttct; SOX2: FW atgggttcggtggtcaagt, REV
ggaggaagaggtaaccacagg; PTEN: FW cagccgttcggaggattat, REV ttctcctc
agcagccagag; NESTIN: FW gaggtggccacgtacaggacc, REV ctgaaagctga
gggaagtcttgga; NOTCH1: FW gctccttccggctgatttat, REV cttaaccaggc
ttggcaca.
Western blots
GSC and U87 cell lysates were analysed by immunoblotting as
described [21], with ZEB1 (HPA027524; Sigma), EGFR (HPA018530;
Sigma), actin (A2066; Sigma), Flag (F3165; Sigma), GAPDH
(MAB374; Millipore) antibodies. Membranes were incubated with
Pierce ECL substrate (Thermo Scientific) and chemiluminescent
images collected by a BioRad ChemiDoc.
ChIP, ChIP-seq and RNA-seq
Samples for ChIP and ChIP-seq assays were prepared and analysed
according to Myers Lab ChIP-seq Protocol v041610 (http://myers.
hudsonalpha.org/documents/) and MAGnify Chromatin Immuno-
precipitation System protocol (Invitrogen). The following antibodies
were used: Myc (sc-764X, Santa Cruz Biotech), Max (c-197X, Santa
Cruz), RNA Pol II (sc-899X, Santa Cruz), RNA Pol II phospho Ser5
(ab5131, Abcam), RNA Pol II phospho Ser2 (ab24758, Abcam and
3E19, Active Motif), Flag (F1804, Sigma). Oligonucleotides used to
amplify chromatin region immunoprecipitated by different antibod-
ies are described in Dataset EV5. Each single ChIP-seq was
performed at least twice independently. For RNA-seq, 2 lg total
RNA purified by PureLinkRNA Mini Kit (Life Technologies) was
used. ChIP-seq and RNA-seq libraries were prepared by Emanuela
Aleo at Istituto di Genomica Applicata (IGA; www.appliedge
nomics.org/) according to Illumina TruSeq DNA and TruSeq RNA
Sample Preparation Guides. Samples were sequenced through Illu-
mina HiSeq 2000 and 2500.
Seq-Data analysis
ChIP-seq
50-bp reads were mapped to hg19 human reference genome (UCSC
Genome Browser) using Bowtie [62] version 0.12.7 allowing three
mismatches; reads with multiple best matches were discarded. Peak
calling was through MACS [63] 1.4.2 with 104 P-value cut-off. The
RefSeq transcript annotation of hg19 was used for computing inter-
sections between peaks and promoters. Binding enrichment to
promoters was calculated by the normalized number of ChIP-seq
reads as Reads Per Million (RPM). In case of multiple TSSs, those
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with the highest enrichment were chosen. Motif enrichment analysis
was through Pscan-ChIP [64].
RNA-seq
The RAP [65] RNA-Seq pipeline Tophat v13 (https://bioinformat-
ics.cineca.it/rap/)—including quality controls, adaptor trimming
and masking of low-quality sequences, tophat2, bowtie and
CuffLinks 2.2—was used to reconstruct the transcriptome (hg19
reference) and calculate expression values as FPKM. Differential
expression was assessed by CuffDiff2, as well as by Fold-Change
thresholds, and Gene Set Enrichment Analysis (GSEA: www.broad-
institute.org/gsea/) subdividing MYC targets in groups of 500 genes.
Accession codes
ChIP-seq and DNA-seq records of data utilized in this study are
accessible via Gene Expression Omnibus (GEO http://www.ncbi.
nlm.nih.gov/geo/), at accession GSE86519.
Expanded View for this article is available online.
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